Dissertation > Excellent graduate degree dissertation topics show

The Influence of Atorvastatin or Rosuvastatin on Antiplatelet Function of Clopidogrel

Author: GengYanPing
Tutor: XieRuiQin;CuiZuo
School: Hebei Medical University
Course: Internal Medicine
Keywords: coronary heart disease clopidogrel rosuvastatin atorvastatin platelet aggregation
CLC: R541.4
Type: Master's thesis
Year: 2009
Downloads: 159
Quote: 0
Read: Download Dissertation


Objective: Platelet activation, aggregation and atherothrombotic play a crucial role in acute coronary syndromes and percutaneous coronary interventions. Clopidogrel inhibits platelet P2Y12 Adenosine diphosphate (ADP) receptor, thus preventing ADP-induced platelet aggregation. Clopidogrel can significant decrease adverse cardiovascular events and the incidence of stent reocclusion in combination with aspirin.Statins have the effection of anti-cholesterol as well as slowing atherosclerosis progression. Many clinical trails have demonstrated that statins can decrease the incidence of cardiocerebral vascular events. Statins are frequently given in conjunction with clopidogrel for therapy of acute coronary syndromes.Clopidogrel is an inactive thienopyridine prodrug. In order to exert its antiplatelet action, clopidogrel requires conversion in the liver into an active metabolite in vivo through cytochrome (CY) P450, mainly theisoenzyme CYP3A4 and CYP3A5. Some statins, such as atorvastatin, lovastatin, simvastatin and cerivastatin, were found to metabolize by the liver cytochrome P3A4. So some researchers thought that it was possible for the statins to reduce the metabolism of clopidogrel to its active metabolite and attenuate its antiplatelet function.Atorvastatin is metabolized by cytochrome P450 3A4 (CYP3A4). Rosuvastatin is metabolized by CYP2C9 slowly, almost not by CYP3A4. In this random control study, we compared the influence of two statins, which are metabolized through different enzyme, on antiplatelet function of clopidogrel.Methods: A total of 60 patients who were diagnosed as coronary heart disease in the second hospital of Hebei Medical University were enrolled between February 2008 and August 2008. 41 patients were with unstable angina and 19 patients were with ST or non-ST elevated acute coronary syndromes. The criteria for exclusion include as the followings: platelet count>300×109/L or<100×109/L; high risk of bleeding tendency; contraindication to aspirin, clopidogrel, statins and low molecular weight heparin; receiving the therapy of statins, or antagonist of platelet membrane glycoproteinⅡb/Ⅲa receptor or clopidogrel within a month.All the patients received standard antiplatelet treatment including aspirin 100 mg/d, clopidogrel 75mg/d and low molecular heparin 5000U/12h by hypodermic injection for five days. Five days after receiving the above medications, patients were randomized to receive atorvastatin 20mg/d as atorvastatin group (n = 30), rosuvastatin 10mg/d as rosuvastatin group (n = 30). Blood samples were obtained at the day before clopidogrel therapy, the day before statin therapy and 3 days after statin therapy. Platelet aggregation was measured with whole blood impedance method induced by adenosine diphosphate (ADP) at 5, 10, and 20μmol/L with a mobile four-channel impedance aggregometer (Chronolog-Log Corporation), which allowed measurement of aggregation beginning 1 hour after blood sampling.Statistical analysis: Continuous variables were expressed as the mean value±standard deviation (SD). Categorical variables were summarized as frequency and compared using chi-square test. Student’s t-test was performed to determine the differences between the two groups. The comparison of determination values before and after administration was evaluated by repeated measure variance analysis. All the statistical analysis was performed using the Statistical Package for Social Sciences software (SPSS13.0). Statistical significance was defined as P<0.05.Results: Baseline clinical characteristics and levels of The maximal platelet aggregation rate (MPAR) at the baseline were comparable between two groups(all P>0.05,Table 1,2). After 5-day clopidogrel treatment, the platelet aggregation induced by ADP was lower than before. But after 3-day statin treatment, atorvastatin in addition to clopidogrel led to a small increase to platelet aggregation, and rosuvastatin led to a small decrease, which was not significant. (all P>0.05). The comparation of MPAR between two groups for the three time points was not significantly different (all P>0.05).Conclusion: Neither atorvastatin (CYP3A4-MET) nor rosuvastatin (non-CYP3A4-MET) attenuated the antiplatelet effects of clopidogrel in the early days during short-term co-medication. And no significant difference was found for antiplatelet effects of clopidogrel between atorvastatin and rosuvastatin.

Related Dissertations

  1. The Effects of Atorvastatin on Expression of Osteopontin in Kidney of the Diabetic Rats Its Molecular Mechanism,R587.2
  2. Antioxidant Effects of Atorvastatin on Vascular Remodeling of Vascular Injury in Mice,R543
  3. Association of Interleukin-6 Gene Polymorphisms with Susceptibility to Coronary Heart Disease in Asian Populations: a Meta-analysis,R541.4
  4. The Myocardial Protection Effect of High-Dose Atorvastatin Pretreatment Before Percutaneous Coronary Intervention in Acute Coronary Syndrome,R541.4
  5. Correlation Analysis between Coronary Lesion Severity and Peripheral Blood Cell CD34~+ Ratio in the Coronary Heart Disease Patients Complicating Diabetes Mellitus,R541.4
  6. The Experimental Study of Atorvastatin with Neuroprotective Effects by Inhibiting MMP-9 and Upregulating TIMP-1 Expression in Rat Stroke Model of Focal Cerebral Ischemia/Reperfusion,R743.33
  7. The Correlation between Type D Personality and Anxiety, Depression in Patients with Coronary Heart Disease,R473.5
  8. The Effects of Clopidogrel on Mesenchymal Stem Cells Transplanted to Rats after Myocardial Infarction,R542.22
  9. Effect and Mechanism of Atorvastatin on Myocardial Fibrosis in Rats after Myocardial Infarction,R542.22
  10. A Study on Psychological Assessment and Intervention for the Patients with Coronary Heart Disease (CHD) in Community Hospital,R541.4
  11. Research on Preparation of Clopidogrel Related Compound A and C and Clopidogrel Crystal Form and Diastereoisomeric Salt,TQ460.6
  12. The Relationship between the Plasma Level of HSP70 and Coronary Heart Disease,R541.4
  13. Different Doses of Atorvastatin Improve the Forward Blood Flow in the No-reflow Rats Associated with Inflammation,R541
  14. S100A12 in Coronary Atherosclerotic Heart Disease Expression and Significance,R541.4
  15. Effect of Rosuvastatin on Expression of MMP-9 mRNA and Protective in Cultured Human Monocyte-macrophages Cell Induced by Oxidized Low Density Lipoprotein,R965
  16. Influence of Atrovastation on MMP-9 and TIMP-1 of Experimental Intracerebral Hemorrhage in Rats,R965
  17. Protective Effects of Atorvastatin on Vascular Endothelial Dysfunction Caused by Lysophosphatidyl Choline,R965
  18. Research of Interleukin-1 Genotype and Its Assocation, Prvotella Intermedia between Chronic Periodontitis and Coronary Heart Disease,R781.4
  19. Relationship of C-reactive Protein Genetic and Periodontal Pathogens Polymorphisms between Chronic Periodontitis and Coronary Heart Disease,R781.4
  20. The prospective study of risk factors for disease of the heart and brain together and gathered,R743
  21. The Changes and Influential Factors of Adiponectin、Apelin and Visfatin in Coronary Heart Disease Patients Accompanied with Abnormal Glucose Metabolism,R587.1

CLC: > Medicine, health > Internal Medicine > Heart, blood vessels ( circulatory ) disease > Heart disease > Coronary arteries ( atherosclerosis ),heart disease (CHD)
© 2012 www.DissertationTopic.Net  Mobile